Page 135 - EJMO-9-2

Eurasian Journal of Medicine and
Oncology
Anticancer effects of phytocomposites

References Cancer Res. 2014;4(6):648-662.

1. Petersen PE. Strengthening the prevention of oral cancer: 12. Prior IA, Lewis PD, Mattos C. A comprehensive survey of
The WHO perspective. Community Den Oral Epidemiol. RAS mutations in cancer. Cancer Res. 2012;72(10):2457-2467.
2005;33(6):397-399. doi: 10.1158/0008-5472.can-11-2612
doi: 10.1111/j.1600-0528.2005.00251.x 13. Rodenhuis S, Slebos RJ, Boot AJ, et al. Incidence and

2. Feller L, Lemmer J. Oral squamous cell carcinoma: possible clinical significance of K-ras oncogene activation
Epidemiology, clinical presentation and treatment. J Cancer in adenocarcinoma of the human lung. Cancer Res.
Ther. 2012;03(4):263-268. 1988;48(20):5738-5741.
doi: 10.4236/jct.2012.34037 14. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic
alterations during colorectal-tumor development. New
3. Sagar S, Ramani P. Tobacco as a trigger for oral squamous England J Med. 1988;319(9):525-532.
cell carcinoma arising in the background of oral submucous
fibrosis: A clinicopathological study. J Popul Ther Clin doi: 10.1056/nejm198809013190901
Pharmacol 2023;30(6). 15. Shibata D, Almoguera C, Forrester K, et al. Detection of c-K-
doi: 10.47750/jptcp.2023.30.06.012 ras mutations in fine needle aspirates from human pancreatic
adenocarcinomas. Cancer Res. 1990;50(4):1279-1283.
4. Nussbaumer S, Bonnabry P, Veuthey JL, Fleury-Souverain
S. Analysis of anticancer drugs: A review. Talanta. 16. Lyu H, Li M, Jiang Z, Liu Z, Wang X. Correlate the TP53
2011;85(5):2265-2289. mutation and the HRAS mutation with immune signatures
in head and neck squamous cell cancer. Comput Struct
doi: 10.1016/j.talanta.2011.08.034 Biotechnol J. 2019;17:1020-1030.
5. Priyadarshini R, Ramasubramanian A, Ramani P, Doble M. doi: 10.1016/j.csbj.2019.07.009
Identification of novel potential herbal drug targets
against beta-catenin in the treatment of oral squamous cell 17. Dou R, Zhang L, Lu T, et al. Identification of a novel HRAS
carcinoma. Asian Pac J Cancer Prev 2024;25(12):4181-4188. variant and its association with papillary thyroid carcinoma.
Oncol Lett. 2018;5(4):4511-4516.
doi: 10.31557/apjcp.2024.25.12.4181
doi: 10.3892/ol.2018.7818
6. Dillard CJ, German JB. Phytochemicals: Nutraceuticals and
human health. J Sci Food Agric. 2000;80(12):1744-1756. 18. Cha Y, Erez T, Reynolds IJ, et al. Drug repurposing from the
perspective of pharmaceutical companies. Br J Pharmacol.
doi: 10.1002/1097-0010(20000915)80:12<1744:AID-JSFA725> 2017;175(2):168-180.
3.0.CO;2-W
doi: 10.1111/bph.13798
7. Burcher JT, DeLiberto LK, Allen AM, Kilpatrick KL,
Bishayee A. Bioactive phytocompounds for oral cancer 19. Priyadarshini G, Sukumaran G, Dilipan E, Ramani P.
prevention and treatment: A comprehensive and critical Targeting oral cancer: In silico docking studies of
evaluation. Med Res Rev. 2023;43(6):2025-2085. phytochemicals on oncogenic molecular markers. Asian
Pac J Cancer Prev 2024;25(6):2069-2075.
doi: 10.1002/med.21969
doi: 10.31557/apjcp.2024.25.6.2069
8. Yadav N, Parveen S, Banerjee M. Potential of nano-
phytochemicals in cervical cancer therapy. Clin Chim Acta. 20. Cui JJ, Tran-Dubé M, Shen H, et al. Structure based drug
2020;505:60-72. design of Crizotinib (PF-02341066), a potent and selective
dual inhibitor of mesenchymal-epithelial transition factor
doi: 10.1016/j.cca.2020.01.035 (C-MET) kinase and Anaplastic Lymphoma Kinase (ALK).
9. Farrand L, Oh SW, Song YS, Tsang BK. Phytochemicals: J Med Chem. 2011;54(18):6342-6363.
A multitargeted approach to gynecologic cancer therapy. doi: 10.1021/jm2007613
BioMed Res Int. 2014;2014:890141.
21. Cui W, Aouidate A, Wang S, Yu Q, Li Y, Yuan S. Discovering
doi: 10.1155/2014/890141 anti-cancer drugs via computational methods. Front
Pharmacol. 2020;11:733.
10. Liu J, Peng Y, Wei W. Cell cycle on the crossroad of
tumorigenesis and cancer therapy. Trends Cell Biol. doi: 10.3389/fphar.2020.00733
2021;32(1):30-44.
22. Prada-Gracia D, Huerta-Yépez S, Moreno-Vargas LM.
doi: 10.1016/j.tcb.2021.07.001 Application of computational methods for anticancer drug
11. Li Z, Li D, Zhang G, et al. Methylation-associated silencing discovery, design, and optimization. Bol Méd Hosp Infant
of MicroRNA-335 contributes tumor cell invasion and Méx. 2016;73(6):411-423.
migration by interacting with RASA1 in gastric cancer. Am J doi: 10.1016/j.bmhimx.2016.10.006

Volume 9 Issue 2 (2025) 127 doi: 10.36922/ejmo.7073